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Potentiation of vincristine by vitamin A against drug-resistant mouse
leukaemia cells
I. Nogae, J. Kikuchi, T. Yamaguchi, M. Nakagawa, N. Shiraishi & M. Kuwano
Department ofBiochemistry, Oita Medical School, Hazama-cho, Oita 879-56, Japan.
Summary Vitamin A has been shown to potentiate the cytotoxic action of anticancer agents like vincristine
(VCR) against drug resistant mouse P388 leukaemia cells. In vitro tests showed enhancement by retinyl acetate
of cytocidal activities of VCR against drug-sensitive leukaemia (P388/S) and VCR-resistant leukaemia
(P388/VCR) cells in culture; retinyl acetate rather specifically potentiated VCR against cultured P388/VCR
cells than P388/S cells. The cellular aceumulation of radioactive VCR was significantly enhanced in cultured
P388/VCR cells when retinyl acetate was present. The efflux of VCR from drug-resistant cells was blocked by
retinyl acetate. The effect of the combination of vitamin A and VCR was also tested in vivo on the life-span
of mice bearing P388/S or P388/VCR. Intraperitoneal administration of retinyl palmitate at 41.75 or
83.5 mg kg- was effective to potentiate the antileukaemic activity of VCR against P388/S bearing mice, and
it also overcame vincristine-resistance in P388/VCR bearing mice.
The development of resistance to anticancer agents is often a
serious clinical problem in the treatment of cancer patients.
The development of a methodology to overcome drug-
resistance would be invaluable (Kuwano et al., 1986). Drug
resistance is circumvented in cultured mammalian tumour
cells in vitro by various membrane active agents such as
verapamil (Fojo et al., 1985; Rogan et al., 1984; Tsuruo et
al., 1981), lysosomotropic amines (Shiraishi et al., 1986),
isoprenoids (Nakagawa et al., 1986) phenothiazine
calmodulin inhibitors (Akiyama et al., 1986) and a bisco-
laurine alkaloid, cepharanthine (Shiraishi et al., 1987). In
vivo studies with animals carrying drug-resistant tumours
have shown that verapamil (Tsuruo et al., 1981) or
isoprenoids (Yamaguchi et al., 1986) are also effective. To
apply such combination therapy clinically, the agents which
overcome drug resistance should be nontoxic. As a plausible
compound to combine, we used vitamin A which is a
membrane active agent. Combination of vitamin A and
anticancer agents has exhibited synergistic antitumour effects
on various tumours in vivo (Akiyama et al., 1981; Cohen &
Carbonne, 1972; Nakagawa et al., 1985; Tomita et al., 1982).
In this report, the effect of vitamin A on drug resistance in
leukaemia cells is studied; some ability of vitamin A to
overcome drug resistance is observed.
Materials and methods
Cell line and cell culture
P388/S, and its resistant subline P388/VCR, were obtained
from Dr M. Inaba (Cancer Chemotherapy Cancer, Japanese
Foundation for Cancer Research, Tokyo, Japan). This
resistant subline was developed by in vivo treatment of drug-
sensitive P388 leukaemia cells (P388/S) with VCR (Inaba et
al., 1979). Both sublines were passaged weekly by i.p.
inoculation in BALB/c x DBA/2 (CDFl) mice (Shizuoka
Agricultural Cooperative Association for Laboratory
Animals, Hamamatsu, Japan) without drug injection. The
relative resistance of each cell line to anticancer agents was
confirmed for each assay because the phenotype of resistance
is relatively unstable under in vitro conditions. Cells from
P388/S or its resistant sublines were suspended in RPMI-
medium (Grand Island Biochemical Co., Grand Island, NY,
USA) supplemented with 10% foetal calf serum (FCS, Flow
Laboratories, Inc., McLean, VA, USA) in the presence of
10,uM 2-hydroxyethyldisulfide (Aldrich Chemical Co., Inc.,
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(Yamaguchi et al., 1986).
and 100 jugml- 1 kanamycin
Chemicals
Radioisotopic compounds and chemicals were obtained from
the following sources: [3H] vincristine (VCR, specific activity,
4.8 Cimmol- 1) from Amersham, UK; VCR and retinyl
acetate (RA) from Sigma Chemical Co., St Louis, MO, USA;
retinyl palmitate (RP), a gift from Hoffman-La Roche, Inc.,
Basel, Switzerland. All of the drugs except RP were freshly
prepared by dissolving in dimethyl sulfoxide or absolute
ethanol. Control experiments were done by adding the same
amounts of dimethyl sulfoxide or ethanol. RP for animal
experiments was dissolved in a detergent, HCO-60 (Nikko
Chemical Co., Tokyo, Japan). All control experiments for in
vivo trials were done by adding the same amounts of HCO-
60.
In vivo antitumour activity
P388/VCR was inoculated at 106 cells per mouse i.p. into
male CDF1 mice. These mice were 5 to 6 weeks of age and
weighed 18 to 22 g. Groups of 6 mice were housed in plastic
cages and were given pelleted food and water ad libitum as
described previously (Yamaguchi et al., 1984, 1986). RP was
injected i.p. daily from day 1 to 8. VCR dissolved in sterile
pysiological saline was also administered simultaneously. The
experiment was terminated on day 30. The therapeutic
response was measured as the mean day of death of 6 mice
group as described previously (Nakagawa et al., 1985;
Yamaguchi et al., 1986).
Assayfor growth curves to test circumvention
ofdrugs resistance
Cell survival was measured to test whether vitamin A could
reverse drug resistance in P388 leukaemia cells in vitro.
P388/S and P388/VCR were seeded in 24 multiwell plates at
a cell density of 2 x 105 cells ml-1 well-1. The cells were then
exposed to various doses of VCR in the absence or presence
of RA for 3 h at 37°C. Drug treatment with anticancer
agents in the absence or presence of RA, 10% serum was
either present or absent in the culture medium. Treatment
for 3 h was found to show maximum effect, and no further
enhancement of the circumventing effect was obtained after
longer treatment than 3h. The medium was then replaced
with RPMI-1640 containing 10% FCS, and the cells were
further incubated for 4 days at 37°C in the absence of drugs.
Cell number was then measured in a model ZB1 Coulter
Counter.
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Assayfor colonyformation in soft agar to
test circumvention ofdrug resistance
Soft agar clonogenic assay was performed after Shoemaker et
al. (1985). One ml of cell suspension of P388/S (2 x 104 cells)
and P388/VCR (105 cells) in RPMI medium containing 0.4%
agar (Difco, Agar Noble), 10% FCS, 10 ,uM 2-hydroxy-
ethyldisulfide and various doses of VCR or/and RA was
added onto a 1 ml of base layer containing 0.5% agar, 10%
foetal calf serum in RPMI in 35 mm plastic dishes. They
were further incubated for 10 days at 37°C and colonies
containing > 10 cells were scored.
Drug accumulation
The cells were seeded at 1 x 106 ml- in 24 well of multi-well
plates and treated with various doses of RA in RPMI-1640
without serum for 3 h at 37°C. Control plates were also
prepared for each assay. The cells were incubated for 1 h
with 1 ml of 26 nM [3H] VCR, and then 1 ml of ice-cold PBS
(g 1- 1; NaCl, 8,0; Na2HPO4. 12H20, 2.9; KCl, 0.2; KH2PO4,
0.2) was added to each well at 4°C. The cell pellets were
harvested by centrifugation and washed three times with
PBS, suspended in 0.9 ml of H20 and 10ml of Scintisol EX-
H (Wako Chemical Co., Osaka, Japan), and their radio-
activity was then measured (Nakagawa et al., 1986).
Drug efflux assay
Cells growing exponentially at 5 x 105 per well and control
plates were incubated in the absence or presence of RA for
3 h at 37°C in RPMI-1640 without serum. Then P388/S in
the presence or absence of RA and P388/VCR in the
presence of RA were treated with 5.2nM [3H] VCR for 1 h
at 37°C. For P388/VCR in the absence of RA, incubation
was with 26nM of [3H] VCR to achieve the equivalent level
of radioactive VCR accumulation. After 1 h incubation, the
cells were washed once with ice-cold PBS at 4°C and efflux
was followed over 120 min at 37°C in serum-free and radio-
isotope-free medium with or without RA. At the time
indicated, cells were harvested and their radioactivity was
determined (Nakagawa et al., 1986).
Drug influx assay
Cells growing exponentially at a density of 5 x 105 per well
and control plates were incubated in glucose-free and serum-
free HANKS balanced salt solution (HBSS) and exposed to
various doses of RA for 3 h. The cells were further incubated
with 1 mM 2,4-dinitrophenol for 10 min to inhibit drug efflux
and followed by exposure to 26nM [3H] VCR for 1 min at
37°C (Nakagawa et al., 1986; Shiraishi et al., 1987). The cells
were then harvested by centrifugation and the radioactivity
associated with them determined.
Differences in drug sensitivity to VCR was observed between
P388/S and P388/VCR: P388/S cell growth was inhibited
50% by 50ng VCRml-1, whereas growth of P388/VCR was
inhibited by 50% at 2,000ng VCRml-1 (Figure la).
P388/VCR thus shows 20- to 40-fold greater resistance to
VCR than the sensitive P388/S. Cellular sensitivity to RA
was found to be similar between P388/S and P388/VCR: the
surviving fraction of both P388/S and P388/VCR was de-
creased by only 10% of the initial fraction when 20 ,ug
RA ml-1 was present. Figure 1 also shows that RA partially
overcomes VCR resistance in P388/VCR. The sensitivity of
P388/VCR to VCR was enhanced 2- to 4-fold higher when
10 or 20jigml-1 RA was present. By contrast, the cellular
sensitivity of P388/S to VCR was not significantly enhanced
by RA (Figure la). Some partial effect of RA on the
circumvention of VCR resistance in mouse leukaemia cells
was observed. Serum contains vitamin A binding proteins
like retinol binding protein or other related proteins (Good-
man, 1984), and serum might therefore interfere with the
circumventing effect of RA against the leukaemia cells. We
thus treated the cells with VCR or/and RA for 3 h under
serum-free conditions, and then constructed the growth
curves. As seen in Figure lb, the circumventing effect of RA
against P388/VCR was magnified. The IC50 for P388/VCR
was 2,000, 600 and 800ng VCR ml-1 in the presence of 0, 10
and 20jug RA ml-1, indicating that RA enhanced the cellular
sensitivity of the resistant cells from 8- to 25-fold. The
cellular sensitivity of P388/S to VCR was slightly (2- to 3-
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Results
Effect ofcombination ofvitamin A on VCR
resistance ofmouse leukaemia cells in culture
P388/VCR is established by repeated administration of VCR
to P388/S leukaemia bearing mice (Inaba & Johnson, 1978).
To determine drug effects in the in vitro assay with
P388/VCR or P388/S cells, we measured cell survival by
constructing cell growth curves and clonogenic assay. We
first treated P388/S or P388/VCR cells in the presence of
VCR or/and RA for 3 h in medium with or without 10%
serum, washed with drug-free fresh medium and followed
incubation in 10% serum-supplemented medium in the ab-
sence of any drug. The cellular sensitivity to drugs of
P388/VCR was compared with that of the parental P388/S
by assaying the growth inhibition in vitro at 4th day after the
treatment. We examined the effect of VCR alone or with RA
on growth of P388/S and P388/VCR when treatment for 3 h
with drugs was performed in the presence of serum.
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Figure 1 Effect of RA on resistance to VCR in P388/VCR cells.
Exponentially growing P388/S (0, A, El) and P388/VCR (0, *,
*) cells were seeded either in 10% serum-supplemented medium
(a) or in serum-free medium (b), and the cells were exposed to
various doses of VCR in the absence (0, 0) or in the presence
of 10 gml - (A, A) and 20pgml 1 (E1, *) of RA for 3h. The
cells were then followed by incubation for a further 4 days in a
drug-free and fresh serum-supplemented medium. Each value is
the average of duplicate dishes.
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fold) enhanced in the presence of 10 and 20pg RAml-1
(Figure lb). Figure 2 shows an example of growth curves of
P388/VCR in the absence of RA at 0, 10 and 20pgml-'.
Although RA alone at 10 or 20ygml-' had a slight effect on
the growth of P388/VCR (Figure 2a), combination with
VCR showed a dramatic reduction in the growth rate
(Figure 2b).
We also tested the effect of RA on drug resistance in
P388/VCR leukaemia cells by clonogenic assay in soft agar.
Since colony forming ability of P388/VCR was found to be
about 1/5 of that of P388/S, we plated a 5-fold greater
number of P388/VCR cells than P388/S cells into each dish.
As seen in Table I, the surviving fraction of P388/VCR
synergistically decreased when combined with 10 pgml- 1
RA. RA enhanced the cellular sensitivity of P388/VCR to
VCR more than 4-fold when 10 or 40ngml-1 VCR was
present (Table I). RA alone at 10pgml-1 only slightly
affected the cell survival of P388/VCR as well as P388/S. RA
also enhanced the cellular sensitivity to VCR of P388/S cell
when 1 ngml- 1 of VCR and RA were combined. Both assays
for measuring cell survival by cell growth and colony form-
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ation showed a circumventing effect against VCR-resistant
leukaemia cells by vitamin A.
Effect of vitamin A on cellular accumulation
of VCR in P338/S and P338/VCR cells
To explore how vitamin A overcomes the drug resistance of
P388/VCR, its effect on the cellular accumulation of anti-
cancer agents as examined. Kinetics for VCR accumulation
were observed for 4 h when P388/S and P388/VCR were
incubated with [3H] VCR at 37°C. The accumulation of
[3H] VCR reached saturation at 1 h in P388/VCR or P388/S
cells. We compared dose-response effects of RA on the
cellular accumulation of [3H] VCR in P388/S and
P388/VCR. Both cell lines were first incubated with various
doses of RA, then [3H] VCR was added to the medium for
1 h. The intracellular level of VCR in P388/VCR was appro-
ximately one-third of that in P388/S. Treatment with RA at
10 to 50pgml-1 enhanced the accumulation of radioactive
VCR in P388/VCR cells by 2- to 3-fold (Figure 3). Treatment
with vitamin A at these doses reduced cell survival by < 10%
of control. Figure 3 also showed enhancement of VCR
accumulation by RA in the sensitive P388/S cells although
the level of enhancement was only - 125%.
Enhanced outward transport (efflux) has been shown to be
associated with drug resistance in mouse P388 leukaemia
cells resistant to anticancer agents (Inaba & Johnson, 1978;
Inaba et al., 1979). We determined whether increased
accumulation of anticancer agents in the resistant leukaemia
cells by vitamin A is due to altered efflux and/or influx. To
test the effect of vitamin A on drug efflux activity, the cells
were exposed to [3H] VCR for 60min, followed by incub-
ation with or without 50pg RAml-1 in medium containing
no isotope (Figure 4). More than 50% of cell associated
radioactive VCR in P388/VCR cells was released into
medium after 30 min of incubation in the absence of RA, and
then there was a slight subsequent release of the radioactivity
at 37°C. In contrast, in the parental cells, the release of VCR
3
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Figure 2 Effect of RA on cell growth of P388/VCR cells in the
absence of the presence of VCR. Growth of P388/VCR cells was
followed in serum-supplemented medium after exposure to 0 (0),
lOgml-' (A) and 2Ougml-1 (D) of RA in the absence (a) or
presence (b) of 1jigml-1 VCR for 3h.
Table I Effect of RA and VCR on colony formation of P388/S and
P388/VCRa
VCR (ngml-1)
RA
Cell lines (10jygml-1) 0 1 10 40
P388/S 100 24.8+ 4.6 0 0
P388/S + 100 10.2+ 3.4 0 0
P388/VCR 100 87.5+10.6 63.0+8.0 31.3+4.1
P388/VCR + 100 50.0+ 8.1 14.0+4.3 0
aRelative survival fraction (%) was presented when colony number
appearing in the absence or presence of RA without VCR was
normalized as 100%. The colony number in the absence of RA was
2058 (P388/S) and 2352 (P388/VCR), and that in the presence of
10igml-1 RA was 1979 (P388/S) and 1568 (P388/VCR). Each value
is average +s.d. from triplicate dishes.
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Figure 3 Effect of RA on drug accumulation in P388/S and
P388/VCR. P388/S (rI) and P388/VCR (0) were seeded and
treated with various doses of RA. P388/S and P388/VCR were
then incubated with [3H] VCR, and the cell-associated radio-
activity was counted.
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Figure 4 Effect of RA on drug efflux. P388/S (0, *) and
P388/VCR (A, A) were seeded and incubated in the presence or
absence of 50pigml-' of RA. After the cells were further
incubated with [3H] VCR, they were exposed to assay medium
in the absence (0, A) or presence (0, A) of 50 ig RA ml- '. The
values are mean +s.d. from triplicate dishes.
into medium proceeded much more slowly, and >50% of the
initial activity still remained after 90min incubation (Figure
4). Efflux of VCR from P388/VCR was significantly blocked
by 50,ug RA ml- ': more than 60% of the initial activity
remained in RA-treated P388/VCR cells even after 120min
incubation (Figure 4). In the sensitive P388/S cells, treatment
with RA did not significantly interfere with drug efflux.
The effect of RA on cellular uptake (influx) of VCR was
also examined (Figure 5). Treatment of P388/VCR with 2,4-
dinitrophenol increased accumulation of VCR only slightly if
at all (c.f. Figures 3 and 5). As a function of dose of RA,
accumulation of VCR into P388/VCR and P388/S increased
about 2-fold (Figure 5).
Effect of vitamin A on antitumour activity of
VCR in P388/S- and P388/VCR-bearing mice
We tested the in vivo effect of vitamin A to potentiate VCR
against drug-resistant leukaemia bearing mice. Since RA is
toxic and unstable in vivo, we used RP for in vivo tests. Our
previous study showed that RP at 167 mg kg- produced
synergistic antitumour activity of various anticancer agents
against P388/S bearing mice (Nakagawa et al., 1985). We
used various doses of RP ranging from 41.75-83.5 mgkg-'.
These doses of RP alone were found to be nontoxic in mice.
We first tested the in vivo effect of RP and VCR on VCR-
resistant P388/VCR bearing mice. VCR at 5, 10 and
30,ugkg- administered daily for 8 days starting from day 1
increased the life-span of P388/S bearing mice significantly,
up to 2-fold (Table II).
We then tested the effect of RP and VCR treatment on
P388/VCR bearing mice. RP alone at 41.75-83.5 mgkg-
gave no therapeutic effect (Table II). To obtain similar
therapeutic effects on P388/VCR bearing mice as on P388/S
bearing mice by VCR alone, 3-fold to 6-fold higher doses of
VCR were required. The combination of VCR with RP
synergistically increased the life-span in all combination trials
o 10 30 50 0 10 30 50
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Figure 5 Effect of RA on drug influx. P388/S (Li]) and
P388/VCR (3) pre-exposed to various doses of RA were further
incubated with 1 mM 2,4-dinitrophenol, and then exposed to
[3H] VCR. The values are mean +s.d. from triplicate dishes.
Table II Effect of RP on antitumour activity of VCR in
P388/S and P388/VCR bearing micea
Survival timeb T/CC T/Vd
Drug and dosage (days) (N) (%)
A. P388/S
Control 9.7 +0.8 100
RP, 83.5 mgkg- ' 10.7+ 1.0 110
RP, 41.75mgkg-1 9.8+0.4 93
VCR, 30pgkg 1 15.7+0.8 162 100
+RP, 83.5mgkg-' 20.8+1.8** 214 132
+RP, 41.75mgkg-' 18.2+2.8** 188 116
VCR, lOpgkg-I 13.8+1.0 142 100
+RP, 83.5 mgkg-' 19.8+ 1.3** 204 144
+RP, 41.75mgkg- 1 15.8+1.5** 163 115
VCR, 5,ugkg-' 12.2+0.8 126 100
+RP, 83.5mgkg-' 15.8+3.1** 163 129
+RP, 41.75mgkg-' 13.7+0.8 141 112
B. P388/VCR
Control 12.5+0.7 100
+RP, 83.5 mgkg- 1 14.0+2.7 112
+RP, 41.75 mgkg- ' 12.0+1.3 96
VCR, 200ougkg 1 16.2+1.7 130 100
+RP, 83.5 mgkg- ' 19.3 +2.1** 154 118
+RP, 41.75 mgkg- ' 20.5 +2.7 164 126
VCR, 100pgkg-1 15.3+1.0 122 100
+RP, 83.5mgkg-' 20.7+2.3** 166 136
+RP, 41.75mgkg-' 17.8+1.5** 142 116
VCR, 30 ugkg 1 13.7+1.4 110 100
+RP, 83.5mgkg-1 16.7+1.2** 134 122
+RP, 41.75mgkg-1 16.8+1.8** 134 122
aCDF1 male mice were given i.p. implants of 106 cells of
P388/S or P388/VCR leukaemia on day 0 and drug was given
i.p. daily from day 1 to 8. Each treated group comprised 6
mice and the controls, 20 mice. b**p<0.05 by Student's t test
as compared to VCR alone. CT/C (%) - increase in mean
survival, treated/control x 100. dT/V (%) at each dose of
VCR, the mean survival time of the treated group divided by
the mean survival time of the group treated with VCR alone.VITAMIN A AND DRUG RESISTANCE 271
of two different doses of VCR with RP by up to 36% (Table
II).
Discussion
Our present study is the first to demonstrate that vitamin A
can circumvent drug resistance in tumour cells. RP partially
overcomes drug resistance in P388/VCR leukaemia bearing
mice while RA overcomes drug resistance in cultured drug-
resistant leukaemia cells. RP itself appears to be less active in
vitro (unpublished data), but it is actively transformed into
retinol-type vitamin A in vivo which is supposed to potent-
iate anticancer agents (Akiyama et al., 1981). Clonogenic
assays and growth curves apparently indicate a cir-
cumventing effect of vitamin A against VCR-resistance in
vitro. During growth curve assays, addition of serum was
found to weaken the circumventing effect of RA during the
short exposure to RA and VCR. Higher doses of RA than
20/igml-1 (see Figure 1) were required to observe effective
circumvention in the presence of serum during the treatment
(unpublished data). Lipid-depleted serum was also found to
weaken the effect of RA (unpublished data), suggesting that
retinyl binding protein or other related protein(s) might
interfere with the RA-induced circumvention of VCR re-
sistance in leukaemia cells. Further study is necessary to
clarify which component in serum is involved in the effect.
The underlying mechanism for drug resistance in tumour
cells has not been completely determined. Decreased intra-
cellular accumulation of anticancer agents has been proposed
to involve the acquisition of drug resistance in tumour cells,
and the decreased cellular levels of anticancer agents is due
to enhanced efflux of drug by drug-resistant tumour cells
(Dan0, 1978; Inaba & Johnson, 1978; Skovsgaard, 1978).
Decreased drug permeability has been considered to be
involved in drug resistance (Biedler & Riehm, 1970; Inaba et
al., 1979; Siegfried et al., 1985). Although it has remained
unclear how the transport system is deranged in drug-
resistant tumour cells, recent study suggests increased bind-
ing of vinblastine and its analogs to the high molecular
weight surface membrane P-glycoprotein specific for multi-
drug resistant tumour cells (Cornwell et al., 1986; Sofa et al.,
1986). Verapamil, a potent agent in the circumvention of
multidrug resistance, inhibits the binding of vinblastine to the
membrane protein (Cornwell et al., 1986). It would be
interesting to determine whether RA interacts with the
specific glycoprotein implicated in multidrug resistance.
The effect of vitamin A on plasma membranes was earlier
shown to involve decreased stability of the membrane phos-
pholipid (Lucy, 1970; Lucy & Dingle, 1964). Alteration of
membrane lipids might secondarily change the membrane
transport system. In this study, RA inhibited efflux of VCR
from P388/VCR cells, resulting in enhanced accumulation of
VCR. Since efflux is enhanced in drug-resistant tumour cells,
any agent which inhibits drug efflux might overcome drug
resistance (Kuwano et al., 1986). Vitamin A like RA
overcomes drug resistance possibly through inhibition of
drug efflux from P388/VCR cells. However, the drug efflux
from drug-sensitive P388/S cells is not enhanced. The
stimulatory effect of vitamin A on VCR accumulation in
P388/S cells appears to be caused by enhanced uptake
activity of the anticancer agent rather than its inhibitory
effect on drug efflux. RP-induced potentiation in vivo of VCR
against P388/S leukaemia bearing mice might be partly due
to its stimulatory effect on the drug uptake activity. On the
other hand, vitamin A and its analogues are powerful
immunological adjuvants (Dressler, 1980; Glaser & Lotan,
1979; Tannock et al., 1972). This immunoadjuvant activity of
vitamin A might also have some influence on the vitamin A
effect in vivo against P388/S as well as P388/VCR leukaemia
bearing mice.
Our recent relevant study has shown that synthetic isopre-
noids with 9- to 10-isoprene chains potentiate various anti-
cancer agents (Ikezaki et al., 1984; Yamaguchi et al., 1984)
and some of them overcome drug resistance to anticancer
agents in vivo as well as in vitro (Nakagawa et al., 1986;
Yamaguchi et al., 1986). The combination of anticancer
agents with these isoprenoids is thus expected to be useful
not only in overcoming drug resistance but also in the
enhancement of the antitumour activities of anticancer
agents. Concerning vitamin A or other retinoids, the
combination of retinol type vitamin A with anticancer agents
causes synergistic antitumour effects against various tumour
cell systems (Akiyama et al., 1981; Cohen & Carbone, 1972;
Nakagawa et al., 1985; Tomita et al., 1982). On the other
hand, blood levels of vitamin A including retinol have been
shown to be decreased in patients with various cancers as
compared to control groups (Atukorala et al., 1986; Ibrahim
et al., 1977). Cancer patients with higher levels of serum
retinol respond more favourably to chemotherapy than those
with lower levels of retinol (Soukop & Calman, 1978). These
reports suggest a close correlation between plasma retinol
levels and efficacy of cancer chemotherapy. Anticancer com-
bination therapy with vitamin A might be expected to
produce improved antitumour effects against drug-sensitive
and drug-resistant populations of cancer cells. Clinical trials
of the vitamin A therapy will be necessary to verify the
above prediction.
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